Sovuna (Hydroxychloroquine Sulfate) Patent Expiration, LOE Window & CMS Spending
Sovuna (Hydroxychloroquine Sulfate) by Novitium: Off-Patent Genericized (AB Competition), 13 AB generics, $25K 2024 CMS Part D & Medicaid spend, and $1,665 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novitium |
| FDA Application & Pathway | N214581 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 13 |
| 2024 CMS Total Public Spend | $25K |
| 2024 Medicare Part D Spend | $25K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,665 intro WAC) |